Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(1):142–146. doi: 10.1111/j.1476-5381.1995.tb16331.x

Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation.

J H Guh 1, S C Chueh 1, F N Ko 1, C M Teng 1
PMCID: PMC1908749  PMID: 7647968

Abstract

1. The effects of various alpha 1-adrenoceptor antagonists and nifedipine on tension responses of human prostate to electrical field stimulation were evaluated in this study. 2. Prazosin (3 x 10(-10) to 10(-8) M) and 5-methyl-urapidil (10(-9) to 3 x 10(-8) M) blocked concentration-dependently the tension responses to electrical field stimulation and completely abolished them in the maximal concentrations (10(-8) M and 3 x 10(-8) M, respectively); in contrast, chloroethylclonidine (CEC), in the maximal concentration of 100 microM, blocked these effects by only 50%. 3. The contractile responses of rat vas deferens and spleen to exogenously-applied alpha 1-adrenoceptor agonists were competitively inhibited by prazosin and 5-methyl-urapidil; in addition, the pA2 values were calculated and the relative potencies with reference to prazosin were obtained. The relative potency of 5-methyl-urapidil in human prostate (0.105) was close to that in rat vas deferens (0.257), which contains primarily putative alpha 1A-adrenoceptors. However, it was much more than that in rat spleen (0.011), which contains primarily putative alpha 1B-adrenoceptors. 4. Nifedipine (10(-8) to 10(-6) M) inhibited concentration-dependently the contractile responses to electrical field stimulation in human prostate; in addition, the inhibition percentages were similar to those to exogenously-applied noradrenaline in rat vas deferens. In contrast, CEC (10 microM), which almost flattened the concentration-response curve of the rat spleen to phenylephrine, only partially inhibited (by 33.1%) the nerve-mediated contraction of human prostate. 5. The involvement of prejunctional alpha 2-adrenoceptors situated on the sympathetic nerve terminals of human prostate was also examined.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
142

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aboud R., Shafii M., Docherty J. R. Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol. 1993 May;109(1):80–87. doi: 10.1111/j.1476-5381.1993.tb13534.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Caine M. Clinical experience with alpha-adrenoceptor antagonists in benign prostatic hypertrophy. Fed Proc. 1986 Oct;45(11):2604–2608. [PubMed] [Google Scholar]
  4. Caine M., Perlberg S., Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978 Dec;50(7):551–554. doi: 10.1111/j.1464-410x.1978.tb06210.x. [DOI] [PubMed] [Google Scholar]
  5. Cotecchia S., Schwinn D. A., Randall R. R., Lefkowitz R. J., Caron M. G., Kobilka B. K. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7159–7163. doi: 10.1073/pnas.85.19.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. García-Sáinz J. A., Romero-Avila M. T., Alcántara Hernández R., Macias-Silva M., Olivares-Reyes A., González-Espinosa C. Species heterogeneity of hepatic alpha 1-adrenoceptors: alpha 1A-, alpha 1B- and alpha 1C-subtypes. Biochem Biophys Res Commun. 1992 Jul 31;186(2):760–767. doi: 10.1016/0006-291x(92)90811-x. [DOI] [PubMed] [Google Scholar]
  7. Gross G., Hanft G., Rugevics C. 5-Methyl-urapidil discriminates between subtypes of the alpha 1-adrenoceptor. Eur J Pharmacol. 1988 Jul 7;151(2):333–335. doi: 10.1016/0014-2999(88)90819-9. [DOI] [PubMed] [Google Scholar]
  8. Han C., Abel P. W., Minneman K. P. Alpha 1-adrenoceptor subtypes linked to different mechanisms for increasing intracellular Ca2+ in smooth muscle. Nature. 1987 Sep 24;329(6137):333–335. doi: 10.1038/329333a0. [DOI] [PubMed] [Google Scholar]
  9. Han C., Li J., Minneman K. P. Subtypes of alpha 1-adrenoceptors in rat blood vessels. Eur J Pharmacol. 1990 Nov 6;190(1-2):97–104. doi: 10.1016/0014-2999(90)94116-f. [DOI] [PubMed] [Google Scholar]
  10. Hanft G., Gross G. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol. 1989 Jul;97(3):691–700. doi: 10.1111/j.1476-5381.1989.tb12005.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hedlund H., Andersson K. E., Larsson B. Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol. 1985 Dec;134(6):1291–1298. doi: 10.1016/s0022-5347(17)47714-7. [DOI] [PubMed] [Google Scholar]
  12. Hieble J. P., Caine M., Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol. 1985 Jan 2;107(2):111–117. doi: 10.1016/0014-2999(85)90048-2. [DOI] [PubMed] [Google Scholar]
  13. James S., Chapple C. R., Phillips M. I., Greengrass P. M., Davey M. J., Turner-Warwick R. T., Milroy E. J., Burnstock G. Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J Urol. 1989 Aug;142(2 Pt 1):438–444. doi: 10.1016/s0022-5347(17)38780-3. [DOI] [PubMed] [Google Scholar]
  14. Jardin A., Bensadoun H., Delauche-Cavallier M. C., Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991 Jun 15;337(8755):1457–1461. doi: 10.1016/0140-6736(91)93140-5. [DOI] [PubMed] [Google Scholar]
  15. Kenakin T. P., Novak P. J. Classification of phenoxybenzamine/prazosin-resistant contractions of rat spleen to norepinephrine by Schild analysis: similarities and differences to postsynaptic alpha-2 adrenoceptors. J Pharmacol Exp Ther. 1988 Jan;244(1):206–212. [PubMed] [Google Scholar]
  16. Kenny B. A., Naylor A. M., Greengrass P. M., Russell M. J., Friend S. J., Read A. M., Wyllie M. G. Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens. Br J Pharmacol. 1994 Apr;111(4):1003–1008. doi: 10.1111/j.1476-5381.1994.tb14843.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kirby R. S., Coppinger S. W., Corcoran M. O., Chapple C. R., Flannigan M., Milroy E. J. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol. 1987 Aug;60(2):136–142. doi: 10.1111/j.1464-410x.1987.tb04950.x. [DOI] [PubMed] [Google Scholar]
  18. Kitada S., Kumazawa J. Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol. 1987 Jul;138(1):158–160. doi: 10.1016/s0022-5347(17)43034-5. [DOI] [PubMed] [Google Scholar]
  19. Lepor H., Tang R., Meretyk S., Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993 Mar;149(3):640–642. doi: 10.1016/s0022-5347(17)36170-0. [DOI] [PubMed] [Google Scholar]
  20. Li D. Y., Varma D. R., Chemtob S. Ontogenic increase in PGE2 and PGF2 alpha receptor density in brain microvessels of pigs. Br J Pharmacol. 1994 May;112(1):59–64. doi: 10.1111/j.1476-5381.1994.tb13029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lomasney J. W., Cotecchia S., Lorenz W., Leung W. Y., Schwinn D. A., Yang-Feng T. L., Brownstein M., Lefkowitz R. J., Caron M. G. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J Biol Chem. 1991 Apr 5;266(10):6365–6369. [PubMed] [Google Scholar]
  22. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol. 1978 May;30(5):312–313. doi: 10.1111/j.2042-7158.1978.tb13237.x. [DOI] [PubMed] [Google Scholar]
  23. Michel M. C., Kerker J., Branchek T. A., Forray C. Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165–1170. [PubMed] [Google Scholar]
  24. Minneman K. P. Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+. Pharmacol Rev. 1988 Jun;40(2):87–119. [PubMed] [Google Scholar]
  25. Minneman K. P., Han C., Abel P. W. Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB 4101. Mol Pharmacol. 1988 May;33(5):509–514. [PubMed] [Google Scholar]
  26. Rampe D., Su C. M., Yousif F., Triggle D. J. Calcium channel antagonists: pharmacological considerations. Br J Clin Pharmacol. 1985;20 (Suppl 2):247S–254S. doi: 10.1111/j.1365-2125.1985.tb02810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schwinn D. A., Lomasney J. W. Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype. Eur J Pharmacol. 1992 Dec 1;227(4):433–436. doi: 10.1016/0922-4106(92)90162-o. [DOI] [PubMed] [Google Scholar]
  28. Schwinn D. A., Page S. O., Middleton J. P., Lorenz W., Liggett S. B., Yamamoto K., Lapetina E. G., Caron M. G., Lefkowitz R. J., Cotecchia S. The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol Pharmacol. 1991 Nov;40(5):619–626. [PubMed] [Google Scholar]
  29. Shapiro A., Mazouz B., Caine M. The alpha-adrenergic blocking effect of prazosin on the human prostate. Urol Res. 1981;9(1):17–20. doi: 10.1007/BF00256833. [DOI] [PubMed] [Google Scholar]
  30. Testa R., Guarneri L., Ibba M., Strada G., Poggesi E., Taddei C., Simonazzi I., Leonardi A. Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol. 1993 Nov 16;249(3):307–315. doi: 10.1016/0014-2999(93)90527-o. [DOI] [PubMed] [Google Scholar]
  31. Vaalasti A., Hervonen A. Autonomic innervation of the human prostate. Invest Urol. 1980 Jan;17(4):293–297. [PubMed] [Google Scholar]
  32. Yamada S., Ashizawa N., Ushijima H., Nakayama K., Hayashi E., Honda K. Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther. 1987 Jul;242(1):326–330. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES